Study Design. Controlled, interventional animal study. Objective. To examine the effect of an inhibitor of acid-sensing ion channel 3 (ASIC3) on pain-related behavior induced by application of the nucleus pulposus (NP) onto the dorsal root ganglion (DRG) in rats. Summary of Background Data. ASIC3 is associated with acidosis pain in inflamed or ischemic tissues and is expressed in sensory neurons and NP cells. The ASIC3 inhibitor, APETx2, increases the mechanical threshold of pain in models of knee osteoarthritis or postoperative pain. However, the efficacy of APETx2 for pain relief in the NP application model remains unknown. Methods. Autologous NP was applied to the left L5 nerve root of 183 adult female Sprague-Dawley rats. The DRGs were treated with NP plus one of the following four treatments: saline solution (SM), low (0.01 mg: LD), medium (0.1 mg: MD), or high dose (1.0 mg: HD) of APETx2. Behavioral testing was performed to investigate the mechanical withdrawal threshold using von Frey hairs. Expression of nerve growth factor, hypoxia-inducible factor1a (HIF1a), activating transcription factor-3, and ionized calciumbinding adaptor molecule-1 was evaluated using immunohistochemistry. Statistical differences among multiple groups were assessed using the Steel test, the Tukey-Kramer test, and the Dunnett test. P < 0.05 were considered significant. Results. The thresholds in the HD group were higher than those in the SM group at Days 14 and 21 (P < 0.05). In the MD group, the threshold was higher than in the SM group at Day 14 (P < 0.05). High doses of APETx2 reduced the expression of HIF1a after Day 14 compared with the SM group (P < 0.05). Conclusion. APETx2 significantly improved pain-related behavior in a dose-dependent manner. APETx2 may inhibit ASIC3 and partly inhibit Nav1.8 channels. This ASIC3 channel inhibitor may be a potential therapeutic agent in early-stage lumbar disc herniation.
L umbar disc herniation (LDH) is one of the most common orthopedic diseases, afflicting many patients with lower back pain, sciatica, and paralysis of lower limbs. The prevalence of LDH is 1% of the general population, with 2,800,000 herniations per year in the United States. 1 The size of the herniated disc does not correspond to LDH symptoms, and a high prevalence (20%-76%) of asymptomatic LDH has been reported. 2, 3 Therefore, not only mechanical factors but also chemical factors are considered to be causes for inducing radiculopathy. The nucleus pulposus (NP) contains inflammatory mediators such as tumor necrosis factor-alpha, interleukin-1-beta, interleukin-6, serotonin, nitric oxide, and nerve growth factor (NGF). [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The model of application of autologous NP does not have a mechanical impact on the nerve, and pain is predominantly because of chemical factors. 15 In some experimental studies, application of NP [14] [15] [16] [17] [18] or chemical factors [4] [5] [6] 19 increases endoneurial fluid pressure, 20 reduces blood flow, and induces inflammation, ischemia (hypoxia inducible factor 1-alpha; HIF1a), 21 tissue acidosis, 22 and changes in ion channels 23, 24 in dorsal root ganglia (DRGs) and pain-related behavior in rats. Furthermore, in terms of electrophysiological neuronal activity, ion channels, particularly sodium channels, are a focus in pain research and are considered important. 23, 24 Acid-sensing ion channels (ASICs), which are sodium channels that belong to the DEGenerin/Epithelial Na þ Channel (DEG/ENaC) family, are activated by low extracellular pH and are associated with acidosis pain in inflamed or ischemic tissues, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] particularly ASIC3, which is mainly expressed in sensory neurons. 36, 37 ASIC3 expression in DRGs was reported in the rat NP model; lidocaine improves the reduction in the pain threshold and suppresses ASIC3 expression in the DRGs. 38 These results suggest that ASIC3 inhibition may be effective for pain relief in patients with lumbar disc herniation. The sea anemone peptide toxin, APETx2, which is an ASIC3 inhibitor, 39 blocks the decrease in intragastric pH and histopathological changes in an acute gastric mucosal lesion model 40 and increases the mechanical threshold in a knee osteoarthritis model 41 and a postoperative pain model 42 in rats. However, no reports have been published on the effect of APETx2 against pain-related behavior induced by NP application on the nerve root in rats. The purpose of this study was to investigate the effect of APETx2 on painrelated behavior induced by the NP in rats.
MATERIALS AND METHODS
The animal experiments were carried out after the approval of the Animal Care and Use Committee in accordance with the Guidelines for Animal Experiments of our university and the Japanese Ministry of the Environment for Law Concerning the Protection and Control of Animals.
Animals and Surgical Procedures
A total of 183 adult female Sprague-Dawley rats (180-220 g; Japan SLC, Shizuoka, Japan) were housed in plastic cages at room temperature (21-248C) with a 12-hour light-dark cycle with free access to food and water. The animals were anesthetized with intraperitoneal injection of 0.1 mL/100 g of mixed anesthetic (0.3 mg medetomidine hydrochloride, 4.0 mg midazolam, and 5.0 mg butorphanol tartrate). The L5 DRG and spinal nerve were exposed by a L5/6 facetectomy. The autologous NP was harvested from the disc of the coccygeal spine and applied to the DRG (NP group). Sham animals underwent the same procedure without NP application to the DRG (sham group). Then, the spinal muscles were sutured, and the skin was closed using metal clips.
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Drug Administration
The ASIC3 inhibitor, APETx2 (Alomone Labs, Jerusalem, Israel), is a peptide toxin produced by the sea anemone, Anthopleura elegantissima. The concentration of APETx2 was adjusted using saline as a solvent. Animals in the NP group were divided into four subgroups: the saline group (SM), the low-dose APETx2 group (0.01 mg, LD), the medium-dose APETx2 group (0.1 mg, MD), and the high-dose APETx2 group (1.0 mg, HD) ( Table 1) . Each animal was administered 0.05 mL drug or saline into the underlayer of the epineurium just distal to the NP at the time of surgery.
Behavioral Testing
To test pain-related behavior, sensitivity to non-noxious mechanical stimulation was measured in the treatment groups (n ¼ 12 per group) using the von Frey test. The rats were placed in a transparent plastic box with a wire netting floor and were allowed to acclimatize for 15 minutes. The mid-plantar surface of the left hind paw was stimulated using von Frey filaments (1.0-26.0 g force; monofilament sensory tester, SAKAI Med, Tokyo, Japan). Stimulation was initiated with the 1.0 g filament, and filaments were sequentially applied to the surface of the paw just until the filament 
Immunoblotting
Immunoblotting for ASIC3 was performed every 7 days for 28 days (n ¼ 6 per group). Naive rats were used as controls (n ¼ 3). The rats were rapidly decapitated under anesthesia, and the left L5 DRGs were removed and frozen in liquid nitrogen. Samples were homogenized in lysis buffer (Cell Signaling Technology, Danvers, MA) containing 2.2 mg/mL 2-mercaptoethanol (SIGMA-ALDRICH, St. Louis, MO). The total protein concentration for each sample was measured using a bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Proteins were separated on a 10% electrophoretic gel (20 mg/lane) (Wako Pure Chemical Industries, Osaka, Japan) in Tris-glycine-SDS buffer (1.5 hrs, 100 V), and then they were transferred to polyyinylidene difluoride filter membranes (EMD Millipore Corporation, Billerica, MA) for 3 hours at 0.08 mA. Then, the membranes were incubated overnight in diluted primary antibody in 5% bovine serum, 1 Â Tris-buffered saline, and 0.1% Tween-20 at 48C with gentle shaking. The following primary and secondary antibodies were used: rabbit anti-ASIC3 (1:2000; Alomone Labs) and goat anti-rabbit IgG conjugated to horseradish peroxidase (1:5000; Santa Cruz Biotechnology Inc., Dallas, TX). Positive bands were visualized using an enhanced chemiluminescence system (ImageQuant LAS 4000, GE Healthcare UK Ltd., Buckinghamshire, England). The signal of positive bands was calculated relative to internal control signals (b-actin-positive bands) using an imaging analysis system (ImageQuant TL, GE Healthcare UK Ltd.). The ratio in naive rats was considered to be 1.
Immunohistochemistry
Immunohistochemistry for HIF1a as a marker of ischemia, activating transcription factor-3 (ATF-3) as a marker of axonal damage, NGF as a marker of a pain-related substance, and ionized calcium-binding adaptor molecule-1 (Iba-1) as a marker of activated microglia was performed on postoperative Days 7, 14, and 21 (n ¼ 6 per group). The rats were euthanized using isoflurane (Wako Pure Chemical Industries), perfused with a fresh solution of 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS), and the left L5 DRG and spinal cord (SC) were removed and subsequently embedded in paraffin. Two sections (6 mm thick) were cut from each DRG and placed on separate slides. Sections were deparaffinized with xylene and rehydrated with 100% ethanol, followed by PBS. After that, they were pretreated with Dako Target Retrieval Solution (Dako North America, Carpinteria, CA) at 978C for 20 minutes to enhance immunoreactivity (IR). Samples were incubated in 2% normal goat serum in PBS/0.3% Triton X-100 for 1 hour at room temperature. Rabbit anti-ATF3 (1:100; Santa 
Statistical analysis
All data are reported as the mean AE standard deviation (SD). Statistical differences between two groups were compared using the Wilcoxon test. Statistical differences among multiple groups were assessed using the Steel test, the Tukey-Kramer test, and the Dunnett test. P < 0.05 were considered significant.
RESULTS
Behavioral Testing
The mechanical withdrawal threshold in the SM group was decreased for up to 28 days (Figure 1 ). In the HD group, the threshold significantly improved at Days 14 and 21 0 mg) ]. In the SM group, the mechanical withdrawal threshold decreased at Day 7 and remained low until Day 28. In the HD group, the threshold significantly improved at Days 14 and 21 compared with the SM group (P < 0.05). In the MD group, the threshold was significantly increased at Day 14 (P < 0.05), but not at Day 28 compared with the SM group. We found no significant differences in the withdrawal threshold between the SM and LD groups. We found no significant differences in ASIC3 intensity among the treatment groups at any time point. Figure 3 . The ratio of NGF-IR neurons in DRG. A, NGF-IR DRG neurons were expressed in the NP and Sham groups (Day 7) (Scale bar 50 mm). On Days 7 and 14, the ratio of NGF-IR neurons in the NP group was significantly higher in the Sham group (P < 0.05). B, NGF-IR DRG neurons were expressed in four treatment groups (Day7) (Scale bar 50 mm). The ratio of NGF-IR neurons in DRG of the treatment groups. In the MD and HD groups, the ratio of NGF-IR neurons in DRG was significanlty lower than other two groups (P < 0.05).
compared with that of the SM group (P < 0.05). In the MD group, the threshold was significantly increased at Day 14 (P < 0.05). We observed no significant differences in the threshold between the SM and LD groups.
Immunoblotting for ASIC3
No significant differences were observed in ASIC3 intensity among the treatment groups at any time point (Figure 2 ).
Immunohistochemical Analyses
The number of NGF-IR neurons in the NP group was higher than in the sham group at Days 7 and 14 (P < 0.05) ( Figure 3A) . The numbers of NGF-IR neurons in both the MD and HD groups were significantly lower than in the SM group (P < 0.05) ( Figure 3B ). The number of ATF-3-IR neurons in the NP group was higher compared with the sham group at Days 7 and 14 (P < 0.05) ( Figure 4A ). In the NP treatment groups, we found no significant difference in ATF-3 expression at any time point ( Figure 4B ). The ratio of HIF1a-IR neurons was higher in the NP (nontreatment) group compared with the sham group (P < 0.05) ( Figure 5A ). In the HD group, the ratio of HIF1a-IR neurons was significantly lower compared with that of the SM group (P < 0.05) ( Figure 5B ). The number of Iba1-IR microglia in the SC was higher in the NP group compared with that in the sham group at each time point (P < 0.05) ( Figure 6A ). We 
DISCUSSION
This study showed the effect of medium and high doses of APETx2 on improving pain-related behavior induced by application of the NP to the rat nerve root. ASIC3 is formed by homo-or heteromeric association of six different subunits: ASIC1a, 43 ASIC1b, 44 ASIC2a, 45, 46 ASIC2b, 47 ASIC3, 25, 27, 36 and ASIC4. 48, 49 Various combinations of subunits have been reported: heteromeric ASIC3þ1a, ASIC3þ1b, and ASIC3þ2b. The half-maximal 50% inhibitory concentration (IC 50 ) of APETx2 has been reported, and different concentrations of APETx2 have inhibitory effects on each heteromeric combination of ASIC3 subunits. 39 The dose of APETx2 (0.044 mM) in the LD group was lower than the IC 50 of the ASIC3 homomeric association (63 nM). APETx2 (0.44 mM) in the MD group has a higher affinity for homomeric ASIC3 (IC 50 : 63 nM) and ASIC3þ2b (IC 50 : 117 nM) channels. Furthermore, APETx2 (4.4 mM) in the HD group has higher affinity for ASIC3þ1a (IC 50 : 2 mM), ASIC3þ1b (IC 50 : 0.9 mM), and ASIC3þ2b. Therefore, these findings suggest that pain-related behavior improved after treatment with medium and high doses of APETx2 in a dosedependent manner.
Spontaneous neural activity in the DRGs 50 and abnormal discharge in dorsal horn neurons are observed in electrophysiological studies after application of NP, 51 and Nav1.8-IR and Nav1.9-IR neurons increase in the DRGs in a rat disc herniation model. 52 Nav1.8 is inhibited by APETx2 (IC 50 : 2.6 mM), 53 a concentration of APETx2 close to that in the HD group. Thus, APETx2 may affect pain-related behavior through both heteromeric associations of ASIC3 subunits and/or Nav1.8. However, Nav1.8-IR neurons are increased only at day 1, 53 and therefore, one of the limitations of this study is that the functions of ASIC3 and Nav1.8 channels were not investigated with electrophysiological techniques, such as the whole-cell patch clamp system. ASIC3 was expressed in this study, and the threshold improved 7 days after administration of APETx2. We observed a time-lag between administration of APETx2 and improvement of the threshold. Therefore, other factors may also affect pain-related behavior. Iba-1-IR microglia in the SC increased 7 days after application of NP. However, APETx2 had no effect on microglia. Microglia plays an important role in neuropathic pain, especially chronic pain. These observations suggest that the inhibitor of ASIC3 and/ or the voltage-dependent sodium channels does not affect chronicity of radiculopathy.
Levels of inflammatory cytokines, interleukins, and pH change the nerve microenvironment because of LDH. In a study of cultured degenerated human intervertebral discs, interleukins, matrix metalloproteinases, Toll-like receptors, NGF, and so on are present in the NP. 54, 55 Chemical factors, such as serotonin and tumor necrosis factor-alpha, play key roles and interact with each other in the early phase, and pain-related behavior induced by the NP is longer lasting than a single application of either chemical factor in the LDH model. 19, 56 NP may induce various conditions and different degrees of inflammation. ASIC3 is expressed in NP cells of the intervertebral disc and plays a key role in protecting NP cells at a low pH. Suppression of ASIC3 induces NP cell apoptosis. 57, 58 In this study, NGF and HIF1a expression was lower after APETx2 treatment. In addition, we found no difference in the expression of a nerve damage marker (ATF-3) in DRGs among the treatment groups. Thus, APETx2 inhibits ASIC3 activity in the applied NP rather than the DRGs, and a decrease in NP cell survival may lead to a decreased influence of inducing inflammation from the NP to the DRGs, leading to improvement in painrelated behavior with medium and high doses of APRTx2. Furthermore, epigalocatechin 3-gallate (EGCG) inhibits the expression of proinflammatory mediators and matrix metalloproteinases in an in vitro intervertebral disc cell culture study, and radiculopathic pain in vivo. 55 The time course of pain-related behavior after EGCG treatment is similar to that in this study. EGCG, which was applied to the DRGs, may inhibit the inflammatory response of NP tissue, and may have less influence on the DRGs than the expression of cytokines and pain-related inflammation. Therefore, although pain-related behavior is induced, the thresholds recover earlier than that in the nontreatment group. This time course of pain-related behavior is similar to the result in this study.
In the clinical situation, nerve root infiltration (NRI) is used for nonsurgical treatment of radicular symptoms caused by LDH. Although a local anesthetic is effective for about 2 hours, some patients obtain relief from their symptoms for a few weeks or months after NRI. The mechanism is not completely understood, but a decrease in intraradicular blood flow 59, 60 and reduction in nerve conduction velocity 59 are associated with radiculopathy. A local anesthetic, or a combination of a local anesthetic and corticosteroids, is used for NRI, although adding corticosteroids is a controversial issue in nerve block treatments. In our previous in vivo studies, corticosteroids reduce the blood flow in the nerve root, 61 and no additional benefit from using corticosteroids was identified. 62 In contrast, lidocaine has a longer-lasting effect in NRI, and therefore, an ion channel blocker is a potential agent for NRI. According to the results in this study, administration of APETx2 involves the same procedure as NRI. Therefore, APETx2 or a combination of APETx2 plus a local anesthetic may be a potential agent for use in NRI for patients with LDH, especially in the early stage of the extruded type of LDH. However, APETx2 has not been tested in humans. We chose the APETx2 concentration according to a published article. 41 A suitable concentration of APETx2 has not been established for clinical use. In addition, the timing of APETx2 administration should be investigated. Another limitation of our study is that the NP was a jelly-like viscous substance, and therefore, the ASIC3 level and NP cell apoptosis in the applied NP could not be examined during the observed time periods.
CONCLUSION
We demonstrated that APETx2 had an effect on pain-related behavior resulting from application of the NP to DRGs. In the clinical situation, this ASIC3 channel inhibitor could be a potential therapeutic agent for NRI in early-stage LDH.
Key Points
An inhibitor of acid-sensing ion channel 3 (ASIC3) attenuated pain-related behavior induced by nucleus pulposus application onto the nerve root in rats. ASIC3 expression in DRGs was observed, but the expression of ASIC3 remained unchanged in the treatment groups. Nerve growth factor immunoreactivity in DRG neurons in the treatment groups was lower than that in the non-treatment group. This ASIC3 channel inhibitor may be a potential therapeutic agent for nerve root infiltration in early-stage lumbar disc herniation.
